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Objectives: To describe a rapid workflow based on the direct detection of Escherichia coli
(Ec) and Klebsiella pneumoniae (Kp) producing CTX-M extended-spectrum β-lactamase
(ESBL) and/or carbapenemases (eg, KPC, VIM) from blood cultures (BCs) and the infec-
tious disease (ID) consulting for timely appropriate antimicrobial therapy.
Methods: This observational, retrospective study included adult patients with a first episode
of Ec or Kp bloodstream infection (BSI) in a large Italian university hospital, where an
inpatient ID consultation team (IDCT) has been operational. Results from the BCs tested for
detecting blaCTX-M, blaKPC, blaNDM, blaOXA-48-like, and blaVIM genes by the eazyplex
®
SuperBug CRE assay in Ec and Kp organisms had been notified for antimicrobial therapy
consulting.
Results: In 321 BSI episodes studied, we found that 151 (47.0%) of Ec or Kp organisms
harbored blaCTX-M and/or blaKPC and/or blaVIM (meantime from BC collection: 18.5 h).
Empirical antimicrobial treatment was appropriate in 21.8% (33/151) of BSIs, namely 5.9%
(3/51) of BSIs caused by KPC/VIM producers and 30.0% (30/100) of BSIs caused by CTX-
M producers. After notification of results, the IDCT modified antimicrobial therapy (mean
time from BC collection: 20 h) such that the proportion of appropriate treatments increased
to 84.8% (128/151) of BSIs, namely 70.6% (36/51) of BSIs caused by KPC/VIM producers
and 92.0% (92/100) of BSIs caused by CTX-M producers.
Conclusion: Our study shows that a rapid diagnostic-driven clinical strategy allowed for
early prescription of potentially effective antimicrobial therapy in BSIs caused by CTX-M
ESBL- and/or KPC/VIM carbapenemase-producing Ec and Kp organisms.
Keywords: Escherichia coli, Klebsiella pneumoniae, bloodstream infection, drug resistance,
targeted therapy, infectious disease consultation
Background
Escherichia coli (Ec) and Klebsiella pneumoniae (Kp) are the leading causes of
bloodstream infections (BSIs) involving gram-negative bacteria, and β-lactams are
among the most used drugs for treatment of such infections. Globally, increasing
attention is being focused on the growing involvement of extended-spectrum-β-
lactamase (ESBL)-producing isolates of Ec and Kp in serious BSIs.1,2 This trend is
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due largely to the emergence of CTX-M ESBLs, a rapidly
expanding group of enzymes that are being encountered with
increasing frequency in both bacterial species.3,4
Carbapenems represent one therapeutic option for infections
caused by multidrug-resistant (MDR) ESBL-producing
organisms; however, resistance to this class of antibiotics
has increased during the last decade.5 Carbapenem-resistant
Enterobacteriaceae, particularly Kp producing blaKPC, are
now responsible for a new dramatic scenario and are emer-
ging as a relevant cause of health care-associated BSIs in
several countries, including Italy.6–8
Detecting rapidly and accurately BSI pathogens is
a critical factor for earlier implementation of effective treat-
ment of these life-threatening infections. Although blood
culture (BC) remains the gold standard for diagnosing BSIs,
the time-consuming process of isolate identification/charac-
terization with conventional culture-based methods has
been improved by the development of faster technologies,
allowing identification of the infecting pathogen directly
from BC bottles.9 In addition to matrix-assisted laser deso-
rption ionization–time of flight mass spectrometry (eg,
MALDI BioTyperTM system [Bruker Daltonics, Bremen,
Germany]), various commercial BC-based nucleic acid
assays can shorten the identification time of pathogens
and/or resistance genes,10 and have added value for anti-
biotic stewardship decisions by decreasing the time to initi-
ating appropriate antibiotic therapy.11–15
To provide rapid pathogens’ characterization for early
appropriate treatment of patients with Ec- or Kp-BSI hospita-
lized in a CTX-M and KPC-endemic setting, we implemented
the laboratory’s BC workflow that uses the eazyplex®
SuperBug CRE assay (Amplex Diagnostics GmbH, Biolife
italiana SRL, Milan, Italy) when Ec or Kp organisms were
identified by direct MALDI BioTyperTM analysis from posi-
tive BCs.10 Clinical experience to date shows that this panel
identifies the CTX-M-1–group and CTX-M-9–group ESBLs
and the VIM (−1 to −37), NDM (−1 to −7), KPC (−2 to −15),
and OXA-48-like (−48, −162, −204, and −244) carbapene-
mases with high accuracy when applied directly to both cul-
tured bacterial and urine samples.16–18 Our workflow was
integratedwith real-time result notification and inpatient infec-
tious disease consultation team (IDCT) intervention. In the
present one-year retrospective study, we assessed whether this
laboratory/clinical workflow may have affected the timely
prescription of appropriate antimicrobial therapy for BSIs
caused by CTX-M ESBL- and/or carbapenemase-producing
Ec or Kp organisms.
Methods
This study was conducted from 15 January 2015 through
15 January 2016 at a 1,200-bed university hospital
(Fondazione Policlinico Universitario A. Gemelli IRCCS,
Università Cattolica del Sacro Cuore, Rome, Italy), under
approval by our institutional Ethics Committee (no.
0040288/16). A central microbiology laboratory, which is
open from 7:00 a.m. to 7:00 p.m., Monday through Friday
and from 7:00 a.m. to 4:00 p.m., Saturday serves all the
hospital wards. The hospital has an IDCT comprising four
ID specialists, who operate on a request basis (via the
hospital’s computerized information system) by the physi-
cians operating in medical and surgical wards (except for
hematology unit and ICU, which have dedicated ID spe-
cialists). The IDCT takes charge of patients at the bedside
within 24 hrs of the request.19 Eligible patients were adults
(≥18 years old) with a first, clinically significant episode
of BC-documented BSI for Ec or Kp. Patients were
excluded if they died or were discharged before BC results
were available, or if they had incomplete data.
Figure 1 depicts the diagnostic workflow used in this study.
When patients’ BC signaled positive in either BACT/
ALERT® VIRTUOTM (bioMérieux, Marcy l’Étoile, France)
or BACTECTM FX (Becton Dickinson, Sparks, MD, USA)
automated systems, aliquots from BC bottle broths were sub-
jected to the direct MALDI BioTyperTM analysis10 and, when
Ec or Kp organisms were identified, the eazyplex® SuperBug
CRE assay was performed. MALDI BioTyperTM identifica-
tions of Ec or Kp organisms were always concordant with
those of reference (culture-based) identification methods
(Figure 1). As described elsewhere,17 the eazyplex®
SuperBug CRE assay relies on a loop-mediated isothermal
amplification (that covers the aforementioned carbapenemase
variants) and a subsequent real-time fluorescence based visua-
lization of the amplification products. For each patient, results
of the laboratory procedure were immediately available to the
IDCT. The microbiologist also informed the in-charge ID
specialist about that identified organisms could harbor bla
genes other than those detected in the eazyplex® SuperBug
CRE assay (eg, TEM/SHV ESBLs, plasmidic AmpC β-
lactamases), which confer non-susceptibility to extended-
spectrum cephalosporins (ESC) or carbapenems (carba).
Antimicrobial minimum inhibitory concentrations (MICs) of
the Ec or Kp isolates identified by the MALDI BioTyperTM
analysis were determined by antimicrobial susceptibility test-
ing (AST) broth microdilution methods and interpreted
according to the European Committee on Antimicrobial
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Susceptibility Testing (EUCAST) breakpoints (version 8.0,
http://www.eucast.org/clinical_breakpoints/). We performed
phenotypic detection of resistance mechanisms according to
the EUCAST guidelines (version 2.0, http://www.eucast.org/
fileadmin/src/media/PDFs/EUCAST_files/Resistance_
mechanisms/). To confirm antimicrobial resistance profiles, all
the Ec and Kp isolates underwent PCR sequencing of the
blaTEM, blaSHV, blaCTX-M, blaKPC, blaNDM, blaOXA-48-like,
blaVIM, and blaAmpC genes.
2,20–22
Diagnostic and clinical definitions
Time to detection of growth (TTD) was the time from
when the BC bottle entered into the BC system to when
it signaled positive. The time to result (TTR) was the time
elapsed between the BC system entry and completion of
the aforementioned direct-detection procedure. We
assessed the appropriateness of antibiotic treatments at
the time of BC collection (empirical therapy) and after
notification of the procedure (targeted therapy) or AST
(definitive therapy) results. We defined the antimicrobial
treatment as appropriate when the patient received the first
(empirical) and/or subsequent (diagnostic-driven) antibio-
tic with known susceptibility by microbiology report.
Results
We studied 321 patients with Ec (n=214) or Kp (n=107) BSIs.
The mean TTD for the patient-unique positive BCs (n=321)
was 10.3 h (range: 2–90 h). ThemeanTTR for the 151 (47.0%)
Ec or Kp organisms harboring blaCTX-M and/or blaKPC and/or
blaVIM (as detected by the MALDI BioTyper
TM analysis and
eazyplex® SuperBugCRE assay)was 18.5 h (range: 3.3–96 h).
The mean ASTwas 51 h (range: 36–141 h) for all the 321 Ec
and Kp isolates, including 106 (33.0%) isolates that were non-
susceptible to ESC but susceptible to carba (ESCR-carbaS
phenotype) (Table 1). Accordingly, ESBL production was
detected in 36.0% (77/214) of the Ec isolates and in 21.5%
(23/107) of the Kp isolates, and all the 100 isolates carried
CTX-MESBLgenes. TheblaCMY-2 gene (not detectable by the
eazyplex® SuperBug CRE assay) was detected in the remain-
ing 1.8% (6/321) of Ec or Kp isolates. The proportions of the
Ec or Kp isolates harboring carbapenemase genes (ESCR-
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Figure 1 Diagnostic workflow using MALDI BioTyperTM analysis/eazyplex® SuperBug CRE assay (direct procedure) or culture-based methods (reference procedure) on
positive blood cultures from E. coli or K. pneumoniae bloodstream infections (BSIs). Results from both the diagnostic procedures were notified to an IDCT for streamlining
the antimicrobial treatments of BSIs.
Abbreviations: ID, identification; IDCT, infectious disease consultation team.
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respectively, with blaKPC-3 being the most commonly detected
gene (Table 1).
Within few hours after BCs were drawn, physicians
started empirical antimicrobial therapy in all the 321
patients. The antibiotics most frequently used were piper-
acillin-tazobactam (24.3%) and fluoroquinolones (23.7%)
followed by carba (16.2%) and ESC (8.7%); when combi-
nation therapy was used, piperacillin-tazobactam plus ami-
kacin (9.3%) was the most frequent antibiotic regimen. In
most cases (85.0%), the physician in charge of the patient
made the choice of the empirical treatment, and did not
use a predefined protocol. As shown in Table 2, empirical
antimicrobial therapy was appropriate in 41.1% (132/321)
of BSIs, with 5.9% (3/51) for KPC/VIM BSIs and 30.0%
(30/100) for CTX-M BSIs (Figure 2).
After notification of results from both the MALDI
BioTyperTM analysis and eazyplex® SuperBug CRE assay,
the IDCT specialists recommended a modification of the
empirical antimicrobial therapy (Table 2). These actions
increased the proportion of appropriate antimicrobial therapy
to 89.1% (286/321), with 92.0% (92/100) for CTX-M BSIs
and 70.6% (36/51) for KPC/VIM BSIs (Figure 2). The
remaining 35 patients, 15 and 8 of whom were infected by
carbapenemase- or CTX-M-producing Ec or Kp organisms,
respectively, received antimicrobial treatments that were dif-
ferent from the previous empirical treatments, but the
selected drug(s) were still inactive (as later documented by
AST on the relative isolates). The drugs were meropenem
plus colistin in 15 patients (all infected with colistin-resistant
KPC-producing Kp isolates), piperacillin-tazobactam in 15
patients (8 with non-CTX M ESBL-producing isolates, 6
with ESCS-CarbaS isolates, and 1 with CMY-producing
isolates), and fluoroquinolones in 5 patients.
Following release of AST results, antimicrobial therapies
were further modified in the 35 aforementioned patients
(Table 2), leading to a proportion of appropriate treatments
up to 99.7% (320/321 patients) (Figure 2). One patient never
received effective therapy, as the infecting Kp isolate was
resistant to all the antibiotics tested (Table 1).
Discussion
To the best of our knowledge, this study is the first large
hospital-based report that has evaluated the effects of the
rapid detection of Ec and Kp isolates producing blaCTX-M or
Table 2 Appropriate empirical or diagnostic-driven antimicrobial treatments stratified by the type of organisms causing bloodstream
infections in 321 patients
No. (%) of appropriate
empirical treatments
No. (%) of modifications leading to appropriate treatments,
according to the results by
MALDI BioTyperTM analysis plus






0/2 (0.0) 2/2 (100) 0/2 (0.0)
CTX-M-producing E. coli
(n=77)
22/77 (28.6) 48/77 (62.3) 7/77 (9.1)
CMY-producing E. coli
(n=5)
1/5 (20.0) 3/5 (60.0) 1/5 (20.0)
ESCS-carbaS E. coli
(n=130)
77/130 (59.2) 44/130 (33.8) 9/130 (6.9)
KPC/VIM-producing
K. pneumoniae (n=49)
3/49 (6.1) 31/49 (63.3) 14/49 (28.6)a
CTX-M-producing
K. pneumoniae (n=23)
8/23 (34.8) 14/23 (60.9) 1/23 (4.3)
CMY-producing
K. pneumoniae (n=1)
1/1 (100) 0/1 (0.0) 0/1 (0.0)
ESCS-carbaS
K. pneumoniae (n=34)
20/34 (58.8) 12/34 (35.3) 2/34 (5.9)
Total organisms (n=321) 132/321 (41.1) 154/321 (48.0) 34/321 (10.6)a
Notes: aThe treatment was not appropriate in 1 (0.3%) of 321 BSIs because the infecting KPC/VIM-producing K. pneumoniae organism had an AST-determined pandrug
resistance phenotype.
Abbreviations: CRE, carbapenemase-resistant Enterobacteriaceae; BSI, bloodstream infection; ESCS-carbaS, extended-spectrum cephalosporin susceptible-carbapenem susceptible.
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blaKPC or blaVIM on the timing of appropriate antimicrobial
therapy. Several recent studies have performed similar
evaluations,11,12,23,24 but all have involved a small number of
patients with CTX-M- and carbaR-BSI, and none of these
studies used the eazyplex® SuperBug CRE assay as a rapid
resistance detection method. Here, integrating this assay with
MALDI BioTyperTM analysis, our diagnostic algorithm
allowed the successful identification of all Ec and Kp produ-
cing blaCTX-M, and/or blaKPC and/or blaVIM, and, more impor-
tantly, the antimicrobial streamlining in the course of BSI.
Therefore, this study has some strengths. First, the results by
the proposed laboratory workflow are obtainable in a mean
time of 18 h, which may help clinicians to provide more
therapy that is effective during the early period of clinical
illness and may facilitate rapid decisions regarding isolating
patients to prevent transmission. Second, the procedure under-
lying this workflow is simple and easy to perform and requires
minimal training. Third, rapidly detecting a specific type of
carbapenemase is particularly important because of the intro-
duction of new antibiotics potentially active against certain
carbapenemases into the clinical practice. In this context, our
workflow is undoubtedly a positive contribution to infection
control/effective treatment of patients.
Prior to the implementation of the rapid BC strategy in
our hospital, we noted significant delays in initiating effec-
tive antimicrobial therapy.2,25 Conversely, based on the
strategy shown here, the IDCT specialists switched 64.7%
of patients with KPC/VIM BSI and 62.0% of patients with
CTX-M BSI from inappropriate empirical antimicrobial
regimen to effective coverage within a mean time of 20 h.
In the remaining 23 patients on inappropriate empirical
therapy, 15 of whom were infected by KPC producers and
eight by CTX-M producers, the original regimen was dis-
continued, but each patient was treated with a drug against
which his/her isolate had displayed resistance in AST test-
ing. All 15 patients with KPC BSI that maintained an
ineffective coverage received a colistin-based regimen.
A problem of considerable importance is the increasing
rate of colistin-resistance among KPC-producing Kp iso-
lates because of its shortage of therapeutic options in
patients with BSIs.26 There is an endemic widespread of
such isolates in Italian healthcare facilities,27,28 and it was
approximately 40% in our hospital.
The ineffective drug was piperacillin-tazobactam in all but
one patients infected by CTX-M producers. Carbapenems
seem to be a suitable option for treating severe infections
due to those organisms; however, their increased use exerts
selection pressure for carbapenem resistance. Therefore,
experts have suggested carbapenem-sparing antibiotic regi-
mens, particularly in settings such as ours where carbapenem-
resistant isolates are common. Although there is emerging
evidence that piperacillin-tazobactam may be a good choice
for treating ESBL BSIs, its role is still controversial, particu-
larly for BSIs from non-urinary sources.29–33 Additionally, the
susceptibility of ESBL producers to piperacillin-tazobactam is



























































Figure 2 Appropriateness of antimicrobial treatments in subgroups defined by the presence of the indicated resistance determinants in 321 patients with Ec or Kp
bloodstream infections. Empirical or targeted antimicrobial therapy was the administration of antibiotics before and after the eazyplex® SuperBug CRE assay results were
available, respectively. Definitive antimicrobial therapy was the administration of antibiotics after the antimicrobial susceptibility testing results were available. Overall,
antimicrobial therapy was appropriate for any antibiotic with known susceptibility by microbiology report.
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Among our isolates, rates of resistance ranged from 31.2% of
CTX-M-producingEc isolates to 73.9% of CTX-M-producing
Kp isolates. Therefore, physicians need to base their decisions
regarding the empirical use of this antibiotic, until suscept-
ibility results are available, on a sound knowledge of the local
susceptibility patterns and the patient’s clinical condition.
This study has some well-acknowledged limitations.
First, as we conducted our analysis in a single center,
the results are not necessarily applicable to other hos-
pitals, particularly those with very low rates of
Enterobacteriaceae infections caused by CTX-M and/
or carbapenemase producers. Second, the eazyplex®
SuperBug CRE assay’s main weakness is its inability
to identify ESBLs other than CTX-M, plasmidic
AmpC, and some OXA-48-like enzymes, which are
found among currently spreading MDR members of
Enterobacteriaceae.4,28 Therefore, without the ability
to detect these resistance determinants, the assay
would miss a significant proportion of resistant isolates
if implemented in settings where isolates harboring
those genes occur.
Conclusion
Our combined use of the MALDI BioTyperTM analysis
and eazyplex® SuperBug CRE assay can be a reliable,
timesaving alternative to the conventional laboratory
diagnosis of BSIs caused by Ec or Kp organisms with
MDR determinants (ie, CTX-M ESBLs and carbapene-
mases). Importantly, this rapid diagnosis can enable
physicians to begin appropriate antimicrobial therapy
precociously. However, the applicability of our diagnos-
tic workflow does depend on the conditions dictated by
aforementioned limitations, as well as further larger
studies are necessary to validate and confirm the present
findings.
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